Abstract
Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
| Original language | English |
|---|---|
| Pages (from-to) | 628-636 |
| Number of pages | 9 |
| Journal | Clinical and Experimental Nephrology |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2016 Aug 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Physiology
- Nephrology
- Physiology (medical)
Cite this
}
Enteric-coated mycophenolate sodium in pediatric lupus nephritis : a retrospective cohort study. / Chou, Hsin Hsu; Chen, Mei Ju; Chiou, Yuan-Yow.
In: Clinical and Experimental Nephrology, Vol. 20, No. 4, 01.08.2016, p. 628-636.Research output: Contribution to journal › Article
TY - JOUR
T1 - Enteric-coated mycophenolate sodium in pediatric lupus nephritis
T2 - a retrospective cohort study
AU - Chou, Hsin Hsu
AU - Chen, Mei Ju
AU - Chiou, Yuan-Yow
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
AB - Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
UR - http://www.scopus.com/inward/record.url?scp=84944908965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944908965&partnerID=8YFLogxK
U2 - 10.1007/s10157-015-1171-6
DO - 10.1007/s10157-015-1171-6
M3 - Article
VL - 20
SP - 628
EP - 636
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
SN - 1342-1751
IS - 4
ER -